H5N1 vaccine-elicited memory B cells are genetically constrained by the IGHV Locus in the recognition of a neutralizing epitope in the hemagglutinin stem

Journal of Immunology

Volumn 195, Issue 2, 2015, Pages 602-610

  Wheatley, Adam K ^a   Whittle, James R R ^a   Lingwood, Daniel ^b   Kanekiyo, Masaru ^a   Yassine, Hadi M ^a   Ma, Steven S ^a   Narpala, Sandeep R ^a   Prabhakaran, Madhu S ^a   Matus Nicodemos, Rodrigo A ^a   Bailer, Robert T ^a   Nabel, Gary J ^c   Graham, Barney S ^a   Ledgerwood, Julie E ^a   Koup, Richard A ^a   McDermott, Adrian B ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c SANOFI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; DNA VACCINE; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN;

ALLELE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE; GENE LOCUS; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IGHV1 69 GENE; IN VIVO STUDY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INTERFEROMETRY; MEMORY CELL; MOLECULAR CLONING; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; AMINO ACID SEQUENCE; B LYMPHOCYTE; BIOSYNTHESIS; BLOOD; CHEMISTRY; CLINICAL TRIAL; CYTOLOGY; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; MOLECULAR GENETICS; PHASE 1 CLINICAL TRIAL; VACCINATION; VIROLOGY;

AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; B-LYMPHOCYTES; EPITOPES; GENETIC LOCI; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; VACCINATION; VACCINES, DNA; VACCINES, INACTIVATED;

EID: 84936803233     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402835     Document Type: Article

References (37)

1. Corti, D., J. Voss, S. J. Gamblin, G. Codoni, A. Macagno, D. Jarrossay, S. G. Vachieri, D. Pinna, A. Minola, F. Vanzetta, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-856.
2. Throsby, M., E. van den Brink, M. Jongeneelen, L. L. Poon, P. Alard, L. Cornelissen, A. Bakker, F. Cox, E. van Deventer, Y. Guan, et al. 2008. Het-erosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3: e3942.
3. Ekiert, D. C., G. Bhabha, M. A. Elsliger, R. H. Friesen, M. Jongeneelen, M. Throsby, J. Goudsmit, and I. A. Wilson. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
4. Sui, J., W. C. Hwang, S. Perez, G. Wei, D. Aird, L.-M. Chen, E. Santelli, B. Stec, G. Cadwell, M. Ali, et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16: 265-273.
5. Dreyfus, C., N. S. Laursen, T. Kwaks, D. Zuijdgeest, R. Khayat, D. C. Ekiert, J. H. Lee, Z. Metlagel, M. V. Bujny, M. Jongeneelen, et al. 2012. Highly conserved protective epitopes on influenza B viruses. Science 337: 1343-1348.
6. Corti, D., A. L. Suguitan, Jr., D. Pinna, C. Silacci, B. M. Fernandez-Rodriguez, F. Vanzetta, C. Santos, C. J. Luke, F. J. Torres-Velez, N. J. Temperton, et al. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120: 1663-1673.
7. Sui, J., J. Sheehan, W. C. Hwang, L. A. Bankston, S. K. Burchett, C.-Y. Y. Huang, R. C. Liddington, J. H. Beigel, and W. A. Marasco. 2011. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin. Infect. Dis. 52: 1003-1009.
8. Ellebedy, A. H., F. Krammer, G.-M. M. Li, M. S. Miller, C. Chiu, J. Wrammert, C. Y. Chang, C. W. Davis, M. McCausland, R. Elbein, et al. 2014. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc. Natl. Acad. Sci. USA 111: 13133-13138.
9. Nachbagauer, R., T. J. Wohlbold, A. Hirsh, R. Hai, H. Sjursen, P. Palese, R. J. Cox, and F. Krammer. 2014. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J. Virol. 88: 13260-13268.
10. Ledgerwood, J. E., K. Zephir, Z. Hu, C.-J. J. Wei, L. Chang, M. E. Enama, C. S. Hendel, S. Sitar, R. T. Bailer, R. A. Koup, et al; VRC 310 Study Team. 2013. Prime-boost interval matters: A randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J. Infect. Dis. 208: 418-422.
11. Li, G. M., C. Chiu, J. Wrammert, M. McCausland, S. F. Andrews, N. Y. Zheng, J. H. Lee, M. Huang, X. Qu, S. Edupuganti, et al. 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl. Acad. Sci. USA 109: 9047-9052.
12. Khurana, S., J. Wu, M. Dimitrova, L. R. King, J. Manischewitz, B. S. Graham, J. E. Ledgerwood, and H. Golding. 2013. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J. Infect. Dis. 208: 413-417.
13. Whittle, J. R., A. K. Wheatley, L. Wu, D. Lingwood, M. Kanekiyo, S. S. Ma, S. R. Narpala, H. M. Yassine, G. M. Frank, J. W. Yewdell, et al. 2014. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J. Virol. 88: 4047-4057.
14. Ledgerwood, J. E., C.-J. Wei, Z. Hu, I. J. Gordon, M. E. Enama, C. S. Hendel, P. M. McTamney, M. B. Pearce, H. M. Yassine, J. C. Boyington, et al; VRC 306 Study Team. 2011. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect. Dis. 11: 916-924.
15. Scheid, J. F., H. Mouquet, N. Feldhahn, B. D. Walker, F. Pereyra, E. Cutrell, M. S. Seaman, J. R. Mascola, R. T. Wyatt, H. Wardemann, and M. C. Nussenzweig. 2009. A method for identification of HIV gp140 binding memory B cells in human blood. J. Immunol. Methods 343: 65-67.
16. Tiller, T., E. Meffre, S. Yurasov, M. Tsuiji, M. C. Nussenzweig, and H. Wardemann. 2008. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329: 112-124.
17. Lingwood, D., P. M. McTamney, H. M. Yassine, J. R. R. Whittle, X. Guo, J. C. Boyington, C.-J. Wei, and G. J. Nabel. 2012. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489: 566-570.
18. Wei, C.-J., J. C. Boyington, P. M. McTamney, W.-P. Kong, M. B. Pearce, L. Xu, H. Andersen, S. Rao, T. M. Tumpey, Z.-Y. Yang, and G. J. Nabel. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329: 1060-1064.
19. Tedder, T. F., L. T. Clement, and M. D. Cooper. 1984. Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J. Immunol. 133: 678-683.
20. Chan, T. D., D. Gatto, K. Wood, T. Camidge, A. Basten, and R. Brink. 2009. Antigen affinity controls rapid T-dependent antibody production by driving the expansion rather than the differentiation or extrafollicular migration of early plasmablasts. J. Immunol. 183: 3139-3149.
21. Wakabayashi, C., T. Adachi, J. Wienands, and T. Tsubata. 2002. A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science 298: 2392-2395.
22. Avery, D. T., J. I. Ellyard, F. Mackay, L. M. Corcoran, P. D. Hodgkin, and S. G. Tangye. 2005. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J. Immunol. 174: 4034-4042.
23. Thomson, C. A., Y. Wang, L. M. Jackson, M. Olson, W. Wang, A. Liavonchanka, L. Keleta, V. Silva, S. Diederich, R. B. Jones, et al. 2012. Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Front. Immunol. 3: 87.
24. Wrammert, J., D. Koutsonanos, G. M. Li, S. Edupuganti, J. Sui, M. Morrissey, M. McCausland, I. Skountzou, M. Hornig, W. I. Lipkin, et al. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208: 181-193.
25. Pappas, L., M. Foglierini, L. Piccoli, N. L. Kallewaard, F. Turrini, C. Silacci, B. Fernandez-Rodriguez, G. Agatic, I. Giacchetto-Sasselli, G. Pellicciotta, et al. 2014. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516: 418-422.
26. Avnir, Y., A. S. Tallarico, Q. Zhu, A. S. Bennett, G. Connelly, J. Sheehan, J. Sui, A. Fahmy, C. Y. Huang, G. Cadwell, et al. 2014. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog. 10: e1004103.
27. Moody, M. A., R. Zhang, E. B. Walter, C. W. Woods, G. S. Ginsburg, M. T. McClain, T. N. Denny, X. Chen, S. Munshaw, D. J. Marshall, et al. 2011. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS ONE 6: e25797.
28. Tan, Y. C., L. K. Blum, S. Kongpachith, C. H. Ju, X. Cai, T. M. Lindstrom, J. Sokolove, and W. H. Robinson. 2014. High-throughput sequencing of natively paired antibody chains provides evidence for original antigenic sin shaping the antibody response to influenza vaccination. Clin. Immunol. 151: 55-65.
29. Miller, M. S., T. Tsibane, F. Krammer, R. Hai, S. Rahmat, C. F. Basler, and P. Palese. 2013. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J. Infect. Dis. 207: 98-105.
30. Miller, M. S., T. J. Gardner, F. Krammer, L. C. Aguado, D. Tortorella, C. F. Basler, and P. Palese. 2013. Neutralizing antibodies against previously encountered influenza virus strains increase over time: A longitudinal analysis. Sci. Transl. Med. 5: ra107.
31. Sasso, E. H., K. Willems van Dijk, A. P. Bull, and E. C. Milner. 1993. A fetally expressed immunoglobulin VH1 gene belongs to a complex set of alleles. J. Clin. Invest. 91: 2358-2367.
32. Sasso, E. H., T. Johnson, and T. J. Kipps. 1996. Expression of the immuno-globulin VH gene 51p1 is proportional to its germline gene copy number. J. Clin. Invest. 97: 2074-2080.
33. Potter, K. N., Y. Li, R. A. Mageed, R. Jefferis, and J. D. Capra. 1999. Molecular characterization of the VH1-specific variable region determinants recognized by anti-idiotypic monoclonal antibodies G6 and G8. Scand. J. Immunol. 50: 14-20.
34. Krammer, F., N. Pica, R. Hai, I. Margine, and P. Palese. 2013. Chimeric hem-agglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87: 6542-6550.
35. Kanekiyo, M., C.-J. Wei, H. M. Yassine, P. M. McTamney, J. C. Boyington, J. R. Whittle, S. S. Rao, W.-P. Kong, L. Wang, and G. J. Nabel. 2013. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499: 102-106.
36. Goff, P. H., D. Eggink, C. W. Seibert, R. Hai, L. Martínez-Gil, F. Krammer, and P. Palese. 2013. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS ONE 8: e79194.
37. Wu, X., T. Zhou, J. Zhu, B. Zhang, I. Georgiev, C. Wang, X. Chen, N. S. Longo, M. Louder, K. McKee, et al; NISC Comparative Sequencing Program. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333: 1593-1602.